Trials / Completed
CompletedNCT02047097
Dimethyl Fumarate (DMF) Observational Study
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,487 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to determine the incidence, type, and pattern of serious adverse events (SAEs), including but not limited to infections (including opportunistic infections), hepatic events, malignancies, and renal events, and of adverse events (AEs) leading to treatment discontinuation in patients with MS treated with dimethyl fumarate (DMF). Secondary objectives of this study in this population are as follows: To determine dimethyl fumarate (DMF) prescription and utilization patterns in routine clinical practice in patients with multiple sclerosis (MS); To assess the effectiveness of dimethyl fumarate (DMF) on multiple sclerosis (MS) disease activity and disability progression in routine clinical practice as determined by the Expanded Disability Status Scale (EDSS) score and multiple sclerosis (MS) relapse information; and To assess the effect of dimethyl fumarate (DMF) on health-related quality of life, healthcare resource consumption, and work productivity.
Detailed description
Patients aged 12 to under 18 may be included where enrollment of pediatric patients in this study is considered observational and is permissible by local regulations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dimethyl fumarate | Provided under routine clinical care |
Timeline
- Start date
- 2013-11-19
- Primary completion
- 2022-10-31
- Completion
- 2022-10-31
- First posted
- 2014-01-28
- Last updated
- 2023-05-24
Locations
468 sites across 22 countries: United States, Argentina, Australia, Austria, Canada, Czechia, Denmark, France, Germany, Hungary, Ireland, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Slovakia, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT02047097. Inclusion in this directory is not an endorsement.